Stock listing

NYSE American:OSTX OS Therapies Incorporated Stock

Home listing (NYSE American) of OS Therapies Incorporated

Follow OS Therapies Incorporated into a list and get an email when it puts out news.

Share price · AMEX:OSTX

$0.803 USD -0.117 (-12.7%)

Close on Nov 20, 2026

Past year -50.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.790 – $0.863 USDNov 20, 2026
Volume
489,720 sharesNov 20, 2026
Market cap
$42.00M USDAt the close on Nov 20, 2026 · price × 52.30M shares outstanding
52-week range
$0.580 – $2.250 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.01M USDMedian day 489,720 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
OS Therapies Incorporated logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:OSTX · Home$0.803 USD-0.117 (-12.7%)489,720$0.809$0.863$0.790$0.920Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:OSTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.803-0.117-12.7%$0.809$0.863$0.790489,720
$0.920+0.175+23.5%$0.747$0.950$0.7471,299,948
$0.745+0.064+9.4%$0.680$0.770$0.6471,163,406
$0.681-0.064-8.6%$0.748$0.750$0.673498,168
$0.745-0.005-0.7%$0.710$0.786$0.680806,102
$0.750-0.122-14.0%$0.879$0.879$0.7221,337,960
$0.872-0.018-2.0%$0.896$0.940$0.860327,347
$0.890-0.030-3.3%$0.958$0.980$0.860404,145
$0.920-0.080-8.0%$0.990$1.080$0.900705,893
$1.000+0.020+2.0%$0.980$1.000$0.840981,548
$0.980-0.170-14.8%$0.986$1.015$0.5803,465,731
$1.150-0.010-0.9%$1.180$1.210$1.110503,303
$1.160+0.010+0.9%$1.160$1.220$1.150439,290
$1.150-0.090-7.3%$1.240$1.300$1.115928,981
$1.240-0.060-4.6%$1.270$1.280$1.210321,618
$1.300+0.050+4.0%$1.250$1.330$1.250388,780
$1.250+0.020+1.6%$1.240$1.280$1.220273,881
$1.230+0.020+1.7%$1.220$1.280$1.200318,053
$1.210-0.040-3.2%$1.270$1.270$1.200247,655
$1.2500.0000.0%$1.270$1.290$1.230142,121
$1.250-0.020-1.6%$1.270$1.310$1.240344,358
$1.270+0.010+0.8%$1.270$1.330$1.250338,045
$1.260-0.010-0.8%$1.300$1.340$1.255320,657
$1.270-0.050-3.8%$1.330$1.340$1.230704,744
$1.320-0.090-6.4%$1.420$1.430$1.300529,171
$1.410+0.020+1.4%$1.380$1.440$1.375375,237
$1.390-0.060-4.1%$1.450$1.480$1.380497,347
$1.450-0.110-7.1%$1.570$1.580$1.450810,557
$1.560-0.060-3.7%$1.610$1.623$1.560247,344
$1.6200.0000.0%$1.620$1.660$1.590422,126
$1.620+0.070+4.5%$1.550$1.680$1.540664,816
$1.550+0.060+4.0%$1.500$1.565$1.464586,742
$1.490-0.110-6.9%$1.710$1.740$1.4706,015,385
$1.600-0.020-1.2%$1.610$1.630$1.565416,202
$1.620+0.010+0.6%$1.625$1.660$1.620233,394
$1.610+0.010+0.6%$1.620$1.650$1.560329,638
$1.600-0.010-0.6%$1.600$1.670$1.590475,091
$1.610-0.040-2.4%$1.640$1.660$1.600549,523
$1.650-0.010-0.6%$1.660$1.679$1.610353,424
$1.6600.0000.0%$1.670$1.680$1.640171,423
$1.660+0.010+0.6%$1.660$1.670$1.615347,757
$1.650-0.120-6.8%$1.760$1.770$1.640654,500
$1.770+0.030+1.7%$1.760$1.840$1.740600,390
$1.740-0.030-1.7%$1.810$1.815$1.740637,059
$1.770-0.060-3.3%$1.810$1.830$1.760908,579
$1.830+0.080+4.6%$1.800$2.000$1.8002,230,933
$1.750-0.030-1.7%$1.790$1.820$1.740421,327
$1.780+0.080+4.7%$1.780$1.810$1.7101,054,087
$1.700+0.020+1.2%$1.650$1.790$1.620993,722
$1.680-0.140-7.7%$1.810$1.840$1.660825,871
$1.820-0.040-2.2%$1.870$1.920$1.810547,914
$1.860+0.030+1.6%$1.830$1.920$1.800393,179
$1.830-0.050-2.7%$1.960$2.015$1.7501,767,807
$1.880+0.060+3.3%$1.840$1.960$1.840982,579
$1.820+0.110+6.4%$1.720$1.840$1.720894,277
$1.710+0.050+3.0%$1.680$1.720$1.610530,467
$1.660-0.030-1.8%$1.680$1.705$1.630400,615
$1.690+0.050+3.0%$1.620$1.690$1.620234,957
$1.640-0.040-2.4%$1.690$1.690$1.600294,984
$1.680+0.030+1.8%$1.650$1.720$1.641518,150
$1.6500.0000.0%$1.650$1.650$1.600351,463
$1.650+0.100+6.5%$1.530$1.650$1.530351,233
$1.550-0.040-2.5%$1.500$1.550$1.460438,883
$1.590+0.010+0.6%$1.560$1.635$1.560386,419
$1.580+0.120+8.2%$1.500$1.580$1.450369,640
Ticker
NYSE American:OSTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All OS Therapies Incorporated news

OS Therapies Incorporated on 6ix

Sector
Health care
Industry
Biotechnology
News releases
41 in the last 12 months · 72 in all · newest Oct 1, 2026 · oldest 2025
Decks
3 decks · latest September 2026

Where OS Therapies Incorporated is listed

ListingExchangeCountryCurrency
NYSE American:OSTX · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:OSTXBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$41.57M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.70

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
OS Therapies Incorporated · AMEX:OSTXUS$42.00MUS$41.57Mn/an/an/an/an/an/a1.70
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
Arecor Therapeutics PLC · LSE:ARECUS$42.40MUS$38.34M48.8×17.1×n/a8.8×38.7%0.0×n/a
Advagene Biopharma Co., Ltd. · TPEX:6709US$41.89MUS$32.02Mn/an/an/a3.9×n/a0.0×n/a
Biomea Fusion, Inc. · NASDAQ:BMEAUS$41.75MUS$15.85Mn/an/an/a5.5×n/a0.1×1.14
Prescient Therapeutics Limited · ASX:PTXUS$41.67MUS$35.83Mn/an/an/a4.4×n/a0.0×n/a
Mereo BioPharma Group plc · NASDAQ:MREOUS$41.52MUS$16.00Mn/a20.0×n/a1.8×n/a0.0×1.34
Elicio Therapeutics, Inc. · NASDAQ:ELTXUS$41.05MUS$19.78Mn/an/an/a2.2×n/a0.5×1.81
MiNK Therapeutics, Inc. · NASDAQ:INKTUS$40.93MUS$33.46Mn/a167×n/an/an/an/a0.81
Median of the othersUS$41.82MUS$17.89M48.8×18.6×3.9×−16.1%0.1×1.51

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
8.25 USD · Analysts' mean
EPS, year to Dec 2026
-0.70 · 3 analysts

Team and board

Officers

OfficerRole
Olivier R. JarryChief Executive Officer
Paul RomnessChair, Chief Executive Officer, President
Chris AcevedoChief Financial Officer
Gerald CommisiongChief Business Officer
Jack DollChief of Staff
John CiccioChief Operations Officer, Syneos Health
Kerry ClemChief Commercial Officer
Robert PetitChief Medical & Scientific Officer, Founding Scientist (OST-HER2)

Board

DirectorRole
Paul RomnessChair, Chief Executive Officer, President
Craig EagleDirector
John CiccioChief Operations Officer, Syneos Health
Karim GalzahrDirector
Theodore SearchDirector

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close+9.4%
Q2 2026Aug 14, 2026 · After close−9.3%
Q1 2026May 18, 2026 · Before open−8.0%
Q3 2025Nov 14, 2025 · After close−5.0%
Q2 2025Aug 18, 2025 · After close−1.4%
Q1 2025May 15, 2025 · After close−1.2%
Q4 2024Mar 31, 2025−17.9%
Q3 2024Nov 15, 2024 · Before open0.0%
Q2 2024Aug 28, 2024−10.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck19 slidesSeptember 2026
Biomarker-focused Conference Call (April 2026)Conference35 slidesApr 30, 2026
Investor Presentation (October 2025)Investor deck28 slidesOct 17, 2025

Open Decks

Financings

RaiseDate
Debt financing
Tranche closed: US$5M raised
Aug 17, 2026
Warrant exercise of common stock purchase warrants exercised or pre-funded for cash under warrant inducement
Announced: US$7.53M · Ceros Capital Markets, a division of Ceros Financial Services, Inc.
Dealers: Ceros Capital Markets, a division of Ceros Financial Services, Inc. (lead)
Use of proceeds: OST-HER2 regulatory filings and commercial preparation, OS Animal Health spinoff preparations, and general corporate purposes
Jan 12, 2026
Warrant exercise of outstanding warrants with $1.12 exercise price exercised under warrant inducement and exchange offer
Closed: US$3.7M raised · US$1.12 a share · Warrants at US$3 · Ceros Financial Services, Inc.
Dealers: Ceros Financial Services, Inc. (lead)
Use of proceeds: Primarily to accelerate OST-HER2 commercial launch preparations in osteosarcoma in the United States
Sep 2, 2025
Shares under Equity Purchase Agreement (equity line of credit)
Cancelled: raise
Buyers: Square Gate Capital Master Fund, LLC — Series 3
Aug 26, 2025
At-the-market programme of common stock
Announced: up to US$18M · B. Riley Securities +1
Dealers: B. Riley Securities, JonesTrading
Aug 19, 2025
Warrant exercise of warrants exercised under warrant exercise inducement and exchange offer
Closed: US$1.76M raised · US$1.12 a share · Warrants at US$3 for 60 months
Use of proceeds: Regulatory and pre-commercial work for OST-HER2 approvals, OS Animal Health alternatives, OST-504 study close-out, AI tADC modeling, general corporate
Jul 14, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$4.00 a share on Jul 31, 2024.

Price
US$4.00 a share
Shares offered
1,600,000 shares of common stock
Offering size
US$6.4 million
Underwriters' option
Up to 240,000 more shares
Listing
OSTX on NYSE American
Underwriter
Brookline Capital Markets
Shares delivered
On or about Aug 2, 2024

Steps

StepWhen
Filed publiclyMay 30, 2024
Amended twiceNewest Jun 13, 2024
Shares registered with an exchangeJul 30, 2024
Declared effective by the SECJul 31, 2024
Final prospectus, with the priceAug 1, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Aug 1, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue00000
Cost of revenue363.1K2.78K4.22K8051.16M4.25K
Gross profit-363.1K-2.78K-4.22K-805-1.16M-4.25K
Research and development16.4M2.84M3.22M3.29M2.17M602
Selling, general and administrative12.3M3.97M1.12M1.15M1.50M795
Operating income-28.7M-6.81M-4.34M-4.45M-4.84M-5.65K
Depreciation and amortization363.1K2.78K4.22K80580567.0K
EBITDA-28.3M-6.81M-4.34M-4.45M-4.84M61.4K
Interest expense02.05M3.45M1.81M2.58M461.8M
Income before tax-28.8M-8.88M-7.79M-6.25M-7.42M-6.03K
Net income-28.8M-8.88M-7.79M-6.25M-7.42M-6.03K
Earnings per share, basic-0.98-1.28-1.46-0.27-0.32-0.00
Earnings per share, diluted-0.98-1.28-1.46

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents269.8K5.53M39.0K171.5K80.8K1.23B
Short-term investments5.53B
Receivables1.15K231.1K430.5M
Current assets332.9K5.53M790.0K496.8K312.8K1.68B
Property, plant and equipment2.49K5.27K8.05K
Total assets6.84M5.54M798.1K509.1K325.9K1.68B
Accounts payable9.94M1.66M2.72M1.23M856.5K40.0K
Current liabilities11.8M4.63M24.7M6.15M3.50M2.10B
Long-term debt10.3M7.07M
Total debt6.05M14.6M10.3M7.07M6.77B
Total liabilities11.9M4.73M24.8M18.1M11.8M8.00B
Shareholders' equity-6.10M-3.27M-24.0M-17.6M-11.5M-6.33B
Shares outstanding37.1M20.9M5.34M23.1M23.1M8.42M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-14.2M-7.28M-3.01M-3.79M-4.40M-2.41B
Capital spending-466.4K000-11.9K-2.01M
Free cash flow-14.7M-7.28M-3.01M-3.79M-4.41M-2.42B
Cash from investing-466.4K1.15K230.9K200.5K158.3M
Cash from financing9.44M12.8M2.87M3.65M3.05M3.48B
Dividends paid-31.3M
Share buybacks6.40B
Change in cash-5.26M5.50M-132.5K90.7K-1.15M1.23B

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
8-K · Current reportNov 12, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
DOct 23, 2026Other filingsSEC
8-K · Current reportOct 19, 2026Material contractSEC
3 · Initial statement of ownershipOct 5, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 5, 2026Insider tradeSEC
8-K · Current reportOct 5, 2026Material contractSEC
S-8 · Registration statement for employee plansSep 18, 2026Offer documentSEC
8-K · Current reportSep 10, 2026Current reportSEC
424B7 · ProspectusSep 10, 2026Offer documentSEC
8-K · Current reportSep 9, 2026Management or board changeSEC
DAug 25, 2026Other filingsSEC
8-K · Current reportAug 21, 2026Material contractSEC
424B5 · ProspectusAug 21, 2026Offer documentSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026Material contractSEC
8-K · Current reportAug 6, 2026Material contractSEC
424B5 · ProspectusAug 6, 2026Offer documentSEC
8-K · Current reportJul 29, 2026Current reportSEC
ARS · Annual report to shareholdersJul 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialJul 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 24, 2026Meeting noticeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
DJul 15, 2026Other filingsSEC
8-K/A · Current report, amendedJul 7, 2026Current reportSEC
8-K · Current reportJul 2, 2026Material contractSEC
10-Q · Quarterly reportMay 18, 2026Quarterly reportSEC
5/A · Annual statement of ownership, amendedMay 15, 2026Insider tradeSEC
NT 10-Q · Late filing noticeMay 15, 2026Explanation requestSEC
8-K · Current reportApr 30, 2026Current reportSEC
8-K · Current reportApr 2, 2026Material contractSEC
424B5 · ProspectusApr 2, 2026Offer documentSEC
8-K · Current reportMar 31, 2026Current reportSEC
424B7 · ProspectusMar 31, 2026Offer documentSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
DMar 6, 2026Other filingsSEC
8-K · Current reportMar 6, 2026Material contractSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4/A · Change in ownership, amendedFeb 13, 2026Insider tradeSEC
8-K · Current reportFeb 13, 2026Current reportSEC
DJan 20, 2026Other filingsSEC
8-K · Current reportJan 12, 2026Material contractSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
S-8 · Registration statement for employee plansOct 31, 2025Offer documentSEC
8-K · Current reportOct 21, 2025Management or board changeSEC
DEFA14A · Additional proxy materialOct 17, 2025Meeting noticeSEC
8-K · Current reportOct 17, 2025Current reportSEC
8-K · Current reportSep 30, 2025Current reportSEC
424B7 · ProspectusSep 30, 2025Offer documentSEC
DSep 10, 2025Other filingsSEC
8-K · Current reportSep 2, 2025Material contractSEC
8-K · Current reportAug 26, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 26, 2025Other filingsSEC
ARS · Annual report to shareholdersAug 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialAug 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementAug 25, 2025Meeting noticeSEC
424B5 · ProspectusAug 25, 2025Offer documentSEC
424B3 · ProspectusAug 25, 2025Offer documentSEC
CORRESP · Letter to the SECAug 21, 2025Other filingsSEC
8-K · Current reportAug 19, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 18, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 18, 2025Quarterly reportSEC
PRE 14A · Preliminary proxy statementAug 15, 2025Meeting noticeSEC
8-K · Current reportAug 15, 2025Current reportSEC
NT 10-Q · Late filing noticeAug 14, 2025Explanation requestSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 13, 2025Other filingsSEC
S-3 · Registration statementAug 8, 2025Offer documentSEC
CORRESP · Letter to the SECAug 8, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 8, 2025Other filingsSEC
S-1 · Registration statementAug 4, 2025Offer documentSEC
DJul 16, 2025Other filingsSEC
8-K · Current reportJul 14, 2025Material contractSEC
8-K · Current reportJun 27, 2025Material contractSEC
8-K · Current reportJun 24, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveJun 9, 2025Other filingsSEC
CORRESP · Letter to the SECJun 2, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 28, 2025Other filingsSEC
S-1 · Registration statementMay 23, 2025Offer documentSEC
8-K · Current reportMay 16, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
144 · Notice of proposed saleMay 7, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 24, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 24, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 21, 2025Offer documentSEC
POS AM · Amendment to an effective registrationApr 21, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeApr 16, 2025Big-stake noticeSEC
8-K · Current reportApr 15, 2025Acquisition or disposalSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
8-K · Current reportApr 9, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialApr 1, 2025Meeting noticeSEC
8-K · Current reportApr 1, 2025Current reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 12, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECMar 10, 2025Other filingsSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 28, 2025Big-stake noticeSEC
DEF 14A · Proxy statementFeb 28, 2025Meeting noticeSEC
3/A · Initial statement of ownership, amendedFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
5 · Annual statement of ownershipFeb 14, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementFeb 7, 2025Meeting noticeSEC
CORRESP · Letter to the SECFeb 7, 2025Other filingsSEC
3 · Initial statement of ownershipFeb 6, 2025Insider tradeSEC
CORRESP · Letter to the SECFeb 5, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 4, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 4, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 4, 2025Other filingsSEC
CORRESP · Letter to the SECJan 31, 2025Other filingsSEC
S-1 · Registration statementJan 31, 2025Offer documentSEC
8-K · Current reportJan 29, 2025Material contractSEC
DJan 21, 2025Other filingsSEC
SCHEDULE 13D · Big-stake noticeJan 17, 2025Big-stake noticeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
8-K · Current reportJan 15, 2025Current reportSEC
4 · Change in ownershipJan 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 14, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveJan 14, 2025Other filingsSEC
S-8 · Registration statement for employee plansJan 13, 2025Offer documentSEC
CORRESP · Letter to the SECJan 10, 2025Other filingsSEC
CORRESP · Letter to the SECJan 3, 2025Other filingsSEC
S-1/A · Registration statement, amendedJan 3, 2025Offer documentSEC
8-K · Current reportJan 3, 2025Material contractSEC
8-K · Current reportDec 30, 2024Material contractSEC
S-1/A · Registration statement, amendedNov 27, 2024Offer documentSEC
CORRESP · Letter to the SECNov 27, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 20, 2024Other filingsSEC
8-K · Current reportNov 15, 2024ResultsSEC
10-Q · Quarterly reportNov 15, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2024Explanation requestSEC
S-1 · Registration statementNov 12, 2024Offer documentSEC
8-K · Current reportNov 1, 2024Material contractSEC
3 · Initial statement of ownershipOct 29, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2024Insider tradeSEC
8-K · Current reportOct 28, 2024Management or board changeSEC
SC 13G · Big-stake noticeAug 28, 2024Big-stake noticeSEC
8-K · Current reportAug 22, 2024Current reportSEC
8-K · Current reportAug 15, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
4 · Change in ownershipAug 6, 2024Insider tradeSEC
424B4 · ProspectusAug 1, 2024Offer documentSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 1, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 1, 2024Other filingsSEC
CERT · Exchange's certificate of listingJul 30, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJul 30, 2024Other filingsSEC
CORRESP · Letter to the SECJul 26, 2024Other filingsSEC
CORRESP · Letter to the SECJul 26, 2024Other filingsSEC
CORRESP · Letter to the SECJun 26, 2024Other filingsSEC
CORRESP · Letter to the SECJun 26, 2024Other filingsSEC
CORRESP · Letter to the SECJun 25, 2024Other filingsSEC
CORRESP · Letter to the SECJun 25, 2024Other filingsSEC

This page holds 200 of 248 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from OS Therapies Incorporated’s releases · as of Nov 13, 2026

Common shares
52,300,709
Fully diluted
52,300,709

Fully diluted

LineSharesAs of
Common shares52,300,709Nov 13, 2026

Warrants and options

Lot
Warrants · US$3.00 · expiry not stated
Warrants · US$3.00 · expire about Jul 2030

Share count over time

CountShares
Nov 13, 202652,300,709

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Vanguard1.02M2.0%US$1.63M+48,636Nov 13, 2026
Geode Capital371K0.71%US$594K+69,154Nov 6, 2026
Howard Financial Services, LTD.248K0.47%US$397KNo changeOct 14, 2026
Citadel246K0.47%US$393KNewNov 16, 2026
BlackRock245K0.47%US$392K+2,668Nov 13, 2026
State Street156K0.30%US$249K+35,700Nov 12, 2026
HighTower Advisors, LLC91,6500.18%US$147K+6,100Nov 9, 2026
Northern Trust82,8510.16%US$133K+12,034Nov 16, 2026
Beacon Pointe Advisors, LLC62,5070.12%US$100KNo changeNov 16, 2026
Equitable Holdings, Inc.52,0000.10%US$83,200NewNov 16, 2026
All 30 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Bridgeway Capital Management, LLC44,2380.08%US$70,781−762Nov 16, 2026
Empowered Funds, LLC44,2380.08%US$70,781NewNov 13, 2026
Hrt Financial LP40,2170.08%US$64,000NewNov 13, 2026
Ingalls & Snyder LLC36,6760.07%US$59,000No changeNov 12, 2026
Stifel Financial Corp27,9000.05%US$44,640No changeNov 12, 2026
Stratos Wealth Advisors, LLC21,3140.04%US$34,103+2,000Nov 13, 2026
Sanders Morris Harris LLC20,0000.04%US$32,000NewOct 14, 2026
Two Sigma18,4800.04%US$29,568−11,934Nov 16, 2026
StoneX Group Inc.14,8530.03%US$22,582NewNov 3, 2026
Jones Financial Companies Lllp13,2990.03%US$22,076−1,202Nov 13, 2026
Morgan Stanley13,0000.02%US$20,800No changeNov 13, 2026
UBS12,8060.02%US$20,489+3,993Nov 10, 2026
Rockefeller Capital Management L.P.7,5000.01%US$12,000No changeNov 13, 2026
Tower Research Capital LLC (TRC)2,647<0.01%US$4,235NewNov 16, 2026
Nuveen1,794<0.01%US$2,888NewNov 10, 2026
BFC Planning, Inc.1,500<0.01%US$2,400No changeNov 13, 2026
Fidelity242<0.01%US$387NewNov 10, 2026
JPMorgan162<0.01%US$261NewNov 12, 2026
Armstrong Advisory Group, Inc100<0.01%US$160No changeOct 9, 2026
Caitong International Asset Management Co., Ltd56<0.01%US$90−7Oct 29, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund416K0.80%US$791K+267KJun 30, 2026
Vanguard Extended Market Index Fund362K0.69%US$687K+108KJun 30, 2026
Fidelity Extended Market Index Fund145K0.28%US$311K+15,457May 31, 2026
iShares Micro-Cap ETF110K0.21%US$210K+49,338Jun 30, 2026
Ultra-Small Company Market Fund45,0000.09%US$85,500+20,000Jun 30, 2026
Fidelity Series Total Market Index Fund34,8840.07%US$74,652+5,670May 31, 2026
Fidelity Total Market Index Fund32,8440.06%US$70,286No changeMay 31, 2026
1290 VT Micro Cap Portfolio7,4360.01%US$14,128+3,356Jun 30, 2026

Big stakes

HolderStakeSharesDate
AYALA PHARMACEUTICALS, INC.9.99%2.16MApr 9, 2025
Thomas A. Satterfield, Jr.9.90%5.43MSep 30, 2026
Shalom Auerbach8.50%2.68MJul 29, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Knuettel Francis II
Other companies: Splash Beverage Group, Inc. (nv) (Director · Since at least Apr 27, 2026); Beeline Holdings, Inc. (Director · Since at least May 14, 2025); Pelthos Therapeutics Inc. (CFO, Treas & Secty · Since at least Feb 15, 2024); Tevogen Bio Holdings Inc. (Chief Financial Officer · Jun 7, 2023 – Jun 7, 2023 · Past); Oceantech Acquisitions I Corp (Chief Financial Officer · Mar 13, 2023 – Mar 13, 2023 · Past); CDT Equity Inc. (Director · Feb 2, 2022 – Feb 2, 2022 · Past); Forum Markets, Incorporated (Director · Jul 2, 2021 – Sep 4, 2023 · Past); Unrivaled Brands Inc (CEO and President, Director · Jun 7, 2021 – Jun 18, 2021 · Past); SCWorx Corp. (Director · Feb 1, 2019 – Nov 26, 2019 · Past); Aqua Metals, Inc. (Chief Financial Officer · May 9, 2018 – Jun 15, 2018 · Past); Spindle Inc (Director · Oct 21, 2015 – Jun 30, 2017 · Past); MARA Holdings, Inc. (CHIEF FINANCIAL OFFICER · May 15, 2014 – Nov 3, 2014 · Past)
Chief Financial Officer · Since at least Nov 10, 2026
Colin Goddard
Other companies: Endocyte Inc (Director · Nov 7, 2013 – Dec 21, 2018 · Past); Human Genome Sciences Inc (Director · Dec 13, 2010 – Jul 30, 2012 · Past); Osi Pharmaceuticals Inc (Chief Executive Officer, Director · Jun 2, 2006 – Jun 7, 2010 · Past)
Director · Jul 31, 2024 – Dec 31, 2024 · Past
Craig Eagle
Other companies: Guardant Health, Inc. (Chief Medical Officer · Since at least May 4, 2021); Telomir Pharmaceuticals, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Q/C Technologies, Inc. (Director · Apr 16, 2021 – Jun 7, 2023 · Past)
Director · Since at least Jul 1, 2026
Olivier R. Jarry
Other companies: DarioHealth Corp. (See Remarks · Aug 30, 2018 – Jan 28, 2020 · Past); Precigen, Inc. (SVP--Consumer Sector · Jun 11, 2015 – Jun 11, 2015 · Past)
Chief Executive Officer · Since at least Oct 28, 2024
Kerry Clem
Other companies: Acorda Therapeutics Inc (Chief Commercial Officer · Sep 9, 2021 – Mar 31, 2023 · Past)
Chief Commercial Officer · Since at least Oct 1, 2026
Robert Petit
Other companies: Advaxis Inc (Chief Scientific Officer · May 3, 2013 – Nov 5, 2018 · Past)
Chief Medical & Scientific Officer, Founding Scientist (OST-HER2) · Since at least Jul 31, 2024
Avril Suzette McKean-DieserDirector · Since at least Oct 28, 2024
Chris AcevedoChief Financial Officer · Since at least Jul 2, 2026
Christopher P AcevedoChief Financial Officer · Since at least Jul 31, 2024
Gerald CommisiongChief Business Officer · Since at least Nov 4, 2026
All 16 people
PersonSeat
Jack DollChief of Staff · Since at least Jul 10, 2025
Joacim BorgDirector · Jul 31, 2024 – Jul 31, 2024 · Past
John CiccioChief Operations Officer, Syneos Health · Since at least Jul 31, 2024
Karim GalzahrDirector · Since at least Jan 28, 2025
Paul RomnessChair, Chief Executive Officer, President · Since at least Jul 31, 2024
Theodore SearchDirector · Since at least Jul 31, 2024

Open People

Log in to ask 6ix AI your own questions about OS Therapies Incorporated.